$HROW

Harrow: Q2 Earnings Snapshot

Harrow, Inc. (HROW) reported a Q2 loss of $17.3 million, or 46 cents per share. Adjusted losses were 34 cents per share. The company’s revenue was $70.7 million, below Zacks-surveyed expectations of $71.1 million and a forecast loss of 23 cents per share. Results missed Wall Street estimates, according to Zacks data.

Original reporting
Published Aug 13, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 12:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$HROW
Bearish
medium confidence
Mentioned
$HROW
Relevance
4/10
alphai data visualization · based on local3news.com
Decision brief

The 30-second read

$HROWBearishLow
01

Why it matters

The key tradable takeaway is the magnitude of the Q2 EPS and revenue misses versus consensus; without guidance or qualitative drivers, the information mainly supports near-term estimate and sentiment risk.

02

Market read

A straightforward earnings miss on both EPS and revenue, likely to pressure the stock and raise the probability of near-term estimate cuts.

03

What to watch

The article omits management commentary, cash flow, backlog, and full-year guidance, which are often the key drivers of post-earnings positioning.

Relevance 4/10Novelty 3/10Timing: reported Q2 results on Monday

Background

AP-style earnings snapshot for Harrow, Inc. (HROW) using Zacks consensus estimates.

Company-level read

Ticker impact

$HROWBearishMedium confidence
Context

Harrow reported Q2 loss of 46 cents per share and revenue of $70.7 million, both missing Zacks/Street expectations.

Expected impact

Likely negative bias for the next session and estimate revisions, absent any offsetting guidance or operational detail.

Evidence & confidence

The article provides only the reported loss and revenue versus consensus; it does not include guidance, margin drivers, or management commentary that could mitigate the miss.

Market effects

Limited read-through to the broader compounding/pharma services sector because the article lacks guidance or industry-specific catalysts.

No clear regional spillover beyond company-specific sentiment.

Primarily company-specific; no global macro or cross-border catalyst mentioned.

Counterpoint

If the miss is driven by amortization or non-cash items, investors may focus on adjusted results (34 cents vs 23 cents) and look for stabilization rather than further downside.

Key entities

  • Harrow, Inc.

    Reported Q2 loss of $17.3 million, EPS loss of 46 cents (adjusted 34 cents), and revenue of $70.7 million.

  • Zacks Investment Research

    Provided Street expectations used for the reported miss (EPS loss 23 cents; revenue $71.1 million).

Related articles

$HROWMedAI 8/10

What's Going On With Harrow Stock Friday? - Harrow (NASDAQ:HROW)

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.

$HROWMed

Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target

Harrow Inc. (HROW) reported H1 2026 revenue of $115M, below expectations, but reaffirmed its full-year guidance of $350M-$365M. Key products IHEEZO, VEVYE, and TRIESENCE showed strong growth, but the company faces a steep H2 revenue target. Harrow also announced a pending deal for TYRVAYA, expected to add $30M in 2027 revenue. Adjusted EBITDA was negative $1.2M for the quarter, and the company has $83.9M in cash.

$HROWMed

Harrow Q2 Earnings Call Highlights

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

$HROWMed

HARROW, INC. (HROW): Results of Operations and Financial Condition

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harrow Announces Second Quarter 2026 Financial Results Second Quarter 2026 and Selected Highlights: ● Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over year ● Reiterated full-year 2026 financial guidance of $350 million to $365 mi